Medical Cannabis
and Life Sciences



Medical cannabis has the potential to help millions of people globally. The stigma is coming down, and the cannabis plant is metamorphosing from a vice steeped in political, legal and cultural controversy to a medicine hailed for its remarkable therapeutic applications. Today, the movement is backed by the tailwinds of favourable legislation, social acceptance, medical recognition and pharmaceutical applications. Cannabis-derived pharmaceutical medicines are now available to treat symptoms associated with multiple sclerosis, certain types of cancer and rare forms of childhood epilepsy, including Lennox-Gastaut syndrome and Dravet syndrome. Our purpose-built investment strategy and ETF – Europe's first truly global medical cannabis ETF – provides investors with access to companies that are positively exposed to the revolution in cannabis-derived medicine. As the medical cannabis movement gathers steam, catalysed by breakthroughs in our understanding of cannabinoids and the corresponding trend towards liberalisation and legalisation, getting on the front foot of this megatrend has its perks for those who can spot the investment opportunity today.


The Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR) seeks to invest in companies that potentially stand to benefit from the increased adoption of cannabis as a medicine, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. FLWR seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Foxberry Medical Cannabis & Life Sciences Index.


  • Favourable Growth Prospects

    FLWR is Europe’s first truly global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.

  • Powered by New Frontier Data®

    FLWR is purpose-built in collaboration with New Frontier Data, an independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the emerging medical cannabis and life sciences sector.

  • Unconstrained Approach

    FLWR’s composition transcends classic sector, size and geographic classifications by tracking an emerging theme.

  • ETF Efficiency

    In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme.

  • SFDR Classification

    FLWR is classified as Article 8.


  • All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
  • FLWR is vulnerable to cyclical declines in the cannabis sector.
  • Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("CRB Activities") would reduce the value of affected companies and FLWR.
  • Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce FLWR’s value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause FLWR and/or FLWR's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("Applicable Laws").
  • FLWR may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause FLWR and/or FLWR's investors to be in breach of Applicable Laws.
  • A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing FLWR in certain countries, de-list FLWR’s Shares from certain stock exchanges; and/or close FLWR.
  • FLWR invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new medicine. Such factors could severely reduce the values of affected companies and FLWR. FLWR also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.
  • FLWR invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.
  • Other: (1) Third party service providers (such as the ICAV’s depositary) may go bankrupt and fail to pay money due to FLWR or return property belonging to FLWR. (2) If the Index provider stops calculating the Index or if FLWR’s license to replicate the Index is terminated, FLWR may have to be closed. (3) It may not always be possible to buy and sell FLWR’s Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of FLWR and investors can lose all the capital invested in FLWR. (5) Please refer to the “Risk Factors” section of the ICAV’s Prospectus and the Fund Supplement.

Fund details

Net Assets USD 59,868,769.32
NAV per share USD 8.9753
Shares Outstanding 6,670,396
Total Expense Ratio 0.65
Inception 12/02/2020
Base Code FLWR
Base Currency USD
Index Name Foxberry Medical Cannabis and Life Sciences Index / FXBYFLWR
Index Replication Method Physical – full replication
Income Treatment Accumulating
No. of holdings 31
Domicile Ireland
Issuer Rize UCITS ICAV
Promoter Rize ETF Limited
Manager Davy Global Fund Management Limited
Investment Manager Davy Global Fund Management Limited
Depositary / Custodian Northern Trust Fiduciary Services (Ireland) Limited
ISA Eligible (UK) Yes
SIPP Eligible (UK) Yes
Reporting Fund Status (UK) Yes
Equity Fund (DE) Yes
SFDR Classification Article 8

Top 10 Holdings

Name ISIN Weight CCY
AMYRIS US03236M2008 13.58 USD
ARENA PHARMS. US0400476075 8.97 USD
NOVARTIS US66987V1098 3.2 USD
ABBVIE US00287Y1091 3.1 USD
TEVA PHARM. INDS. US8816242098 2.79 USD

Full fund holdings


Exchange Currency Listing Date SEDOL Bloomberg Ticker RIC
Deutsche Börse Xetra EUR 17-Feb-20 BJXRZL6 BLUM GY BLUG.DE
London Stock Exchange USD 18-Feb-20 BJXRZC7 FLWR LN FLWR.L
London Stock Exchange GBP 18-Feb-20 BK5TNN5 FLWG LN FLWG.L
SIX Swiss Exchange CHF 09-Jul-20 BJXRZF0 FLWR SE FLWR.S


  • Austria
  • Denmark
  • Finland
  • Germany
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Fund documents

All other documents

Contact Us

Please note that we do not provide investment advice and we will only respond to general enquiries. We will not respond to any queries related to your individual circumstances. Individual investors are required to contact their professional adviser/broker for any investment related queries.

  • 1
  • 2
  • 3

Select Your Country

United Kingdom

Select Your Investor Type